Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM1Z9G)

Drug Name
Vutrisiran Drug Info
Synonyms ALN-TTRsc02
Indication
Disease Entry ICD 11 Status REF
Hereditary amyloidosis 5D00.2 Approved [1]
Transthyretin familial amyloid cardiomyopathy 5D00.20 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMM1Z9G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Transthyretin messenger RNA (TTR mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Patisiran DMWSA0V Amyloidosis 5D00 Approved [4]
Eplontersen DMON9CY Amyloid polyneuropathy 5D00.20 Approved [5]
Revusiran DM5E73H Amyloidosis 5D00 Phase 3 [4]
ISIS-TTR DM4U5NF Amyloidosis 5D00 Phase 3 [6]
ALN-TTR01 DMCSEUY Amyloidosis 5D00 Phase 1 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transthyretin messenger RNA (TTR mRNA) TTPOYU7 TTHY_HUMAN Inhibitor [3]

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215515.
2 ClinicalTrials.gov (NCT03759379) HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
4 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
5 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217388
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
7 Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.